Study unlocks key information on major drug target for psychiatric and cognitive disorders, including schizophrenia

An international study led by Monash University has, for the first time, harnessed cutting-edge technology to reveal new and unprecedented information of how a special class of drugs, known as "allosteric modulators" work at the M4 muscarinic receptor, a major target for notoriously difficult-to-treat psychiatric disorders associated with cognitive deficits, such as schizophrenia.